Entero Therapeutics, Inc. announced a 1 for 3 reverse stock split of its common stock, effective on August 18, 2025.
The reverse stock split was approved by the Board of Directors and shareholders as part of a plan to regain compliance with Nasdaq listing requirements.
This action will reduce the outstanding common stock from approximately 4.77 million shares to approximately 1.59 million shares.
Reverse Stock Split
Entero Therapeutics, Inc. implements a 1 for 3 reverse stock split to meet Nasdaq listing requirements.
Approval Process
The reverse stock split was approved by the Company's Board of Directors and shareholders.
Impact on Outstanding Shares
The reverse stock split will reduce outstanding common stock from 4.77 million shares to 1.59 million shares.
- The reverse stock split aims to maintain the Company's listing on the Nasdaq market, enhancing its visibility and credibility.
- Shareholders who would receive fractional shares will be compensated with cash instead.
The reverse stock split by Entero Therapeutics, Inc. reflects a strategic move to meet Nasdaq listing requirements and enhance shareholder value.